Last reviewed · How we verify
Active Ankylosing Spondylitis
Approved treatments
- Induction- PF-06480605 450 mg SC Q4W · Pfizer
PF-06480605 is a small molecule that targets the IL-17 pathway to treat inflammatory conditions. - tumor necrosis factor inhibitors (TNFi) · Pfizer
- TNF Inhibitor · Pfizer
- TNF Inhibitor · Pfizer
- TNF Inhibitor · Pfizer
- TNF Inhibitor · Pfizer
- TNF Inhibitor · Pfizer
- TNF Inhibitor · Pfizer
- TNF Inhibitor · Pfizer
- TNF Inhibitor · Pfizer
- TNF Inhibitor · Pfizer
- TNF Inhibitor · Pfizer
- TNF Inhibitor · Pfizer
- TNF Inhibitor · Pfizer
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Active Ankylosing Spondylitis patent landscape — cliff calendar, originator estates, attackable patents
- Active Ankylosing Spondylitis treatment landscape brief
- Active Ankylosing Spondylitis treatment updates RSS
Frequently asked questions about Active Ankylosing Spondylitis
What drugs treat Active Ankylosing Spondylitis?
Tracked treatments include Induction- PF-06480605 450 mg SC Q4W, tumor necrosis factor inhibitors (TNFi), TNF Inhibitor.
What is the treatment for Active Ankylosing Spondylitis?
Standard treatment for Active Ankylosing Spondylitis includes Induction- PF-06480605 450 mg SC Q4W, tumor necrosis factor inhibitors (TNFi), TNF Inhibitor. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Active Ankylosing Spondylitis patent cliff · Active Ankylosing Spondylitis CI report
- Treatment: Induction- PF-06480605 450 mg SC Q4W · Pfizer
- Treatment: tumor necrosis factor inhibitors (TNFi) · Pfizer
- Treatment: TNF Inhibitor · Pfizer
- Treatment: TNF Inhibitor · Pfizer
- Treatment: TNF Inhibitor · Pfizer
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing